Survodutide

Survodutide is an investigational dual GLP-1/glucagon receptor agonist developed for obesity, MASH (Metabolic Associated Steatohepatitis), and cirrhosis. It promotes significant weight loss, improves liver markers, reduces visceral adiposity, and increases energy expenditure. Human trials report robust reductions in body weight and promising outcomes in liver disease settings. Developed by Boehringer Ingelheim, it is currently in clinical trials.

• Dual agonist for GLP-1 and glucagon receptors
• Suppresses appetite and food intake
• Enhances energy expenditure and lipolysis
• Improves hepatic insulin sensitivity and glucose homeostasis

• unit: mg

  low dose: 0.6

  frequency: Weekly

  high dose: 4.8

  standard dose: 2.4

  administration route: Subcutaneous (SQ)

• Administer once weekly. Titrate starting from 0.6 mg to target dose (2.4–4.8 mg) over several weeks. Monitor body weight, liver function tests, and glycemic parameters. Continuous use protocol under practitioner supervision.

common: ["Gradual titration mitigates GI tolerability issues"]

sequence: Specific proprietary sequence related to GLP-1 and glucagon.

half life: Supports once-weekly dosing; estimated half-life 4–6 days

degradation: Metabolized hepatically and renally excreted

molecular weight: 4000

molecular formula: C172H265N43O51

tissue specificity: Acts on liver, pancreas, adipose tissue, and CNS appetite-regulating centers

• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.clinicalPMID 38847460 ↗
• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: phase 2 trial.clinicalPMID 38330987 ↗